Clinical significance of expression of urokinase-type plasminogen activator in patients with prostate cancer

Anticancer Research

Volumn 23, Issue 3 C, 2003, Pages 2945-2950

  Ohta, Shoichiro ^a   Fuse, Hideki ^a   Fujiuchi, Yasuyoshi ^a   Nagakawa, Osamu ^a   Furuya, Yuzo ^a  

^a UNIVERSITY OF TOYAMA   (Japan)

Author keywords

Immunohistochemistry; Prostate cancer; Urokinase type plasminogen activator

Indexed keywords

BIOLOGICAL MARKER; MONOCLONAL ANTIBODY; UROKINASE;

ADULT; AGED; ARTICLE; BONE METASTASIS; CANCER GROWTH; CANCER SURVIVAL; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOPLASM; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; PROTEIN EXPRESSION; SURVIVAL RATE; TISSUE SECTION;

AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; BIOPSY; BONE NEOPLASMS; DISEASE PROGRESSION; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; PARAFFIN EMBEDDING; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; URINARY PLASMINOGEN ACTIVATOR;

EID: 0041622641     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Neal DE and Donovan JL: Prostate cancer: to screen or not to screen? Lancet Oncol 1: 17-24, 2000.
2. Niiya K, Shinbo M, Ozawa T, Hayakawa Y and Sakuragawa N: Modulation of urokinase-type plasminogen activator gene expression by inflammatory cytokines in human pre-B lymphoma cell line RC-K8. Thromb Haemost 74: 1511-1515, 1995.
3. Boyd D, Florent G, Kim P and Brattain M: Determination of the levels of urokinase and its receptor in human colon carcinoma cell lines. Cancer Res 48: 3112-3116, 1988.
4. de Bruin PA, Griffioen G, Verspaget HW, Verheiken JH and Lamers CB: Plasminogen activators and tumor development in the human colon: activity levels in normal mucosa, adenomatous polyp, and adenocarcinomas. Cancer Res 47: 4654-4657, 1987.
5. Kirchheimer JC, Huber K, Wagner O and Bincer BR: Pattern of fibrinolytic parameters in patients with gastrointestinal carcinomas. Br J Haematol 66: 85-89, 1987.
6. Duffy MJ, O' Grady P, Devaney D, O' Siorain Fennelly JJ and Lijnen HJ: Urokinase-plasminogen activator, a marker for aggressive breast carcinomas. Preliminary report. Cancer 62: 531-533, 1988.
7. Ohta S, Niiya K, Sakuragawa N and Fuse H: Induction of urokinase-type plasminogen activator by lipopolysaccharide in PC-3 human prostatic cancer cells. Thromb Res 97: 343-347, 2000.
8. Gleason DF and Mellinger GT: The Veterans Administration Cooperative Urological Research Group: Prediction of prognosis for prostate adenocarcinoma by combined histological grading and clinical staging. J Urol 111: 58-64, 1974.
9. Tanji N, Yokoyama M, Sugimoto T, Takeuchi M and Terada N: Apoptosis in prostatic adenocarcinomas: a study of relationship to Ki-67 and Bcl-2 protein expression. Anticancer Res 18: 1111-1116, 1998.
10. Costantini V, Sidoni A, Deveglia R, Cazzato OA, Bellezza G, Ferri I, Bucciarelli E and Nenci GG: Combined overexpression of urokinase, urokinase receptor, and plasminogen activator inhibitor-1 is associated with breast cancer progression. Cancer 77: 1079-1088, 1996.
11. Xing R and Rabbani S: Regulation of urokinase production by androgens in human prostate cancer cells: Effect on tumor growth and metastases in vivo. Endocrinology 140: 4056-4064, 1999.
12. Achbarou A, Kaiser S, Tremblay G, Ste-Marie LG, Brodt P, Goltzman D and Rabbani SA: Urokinase overproduction results in increased skeletal metastasis by prostate cancer cells in vivo. Cancer Res 54: 2372-2377, 1994
13. Rabbani SA, Harakidas P, Davidson DJ, Henkin J and Mazar AP: Prevention of prostate-cancer metastasis in vivo by a novel synthetic inhibitor of urokinase-type plasminogen activator (uPA). Int J Cancer 63: 840-845, 1995.
14. Kirchheimer J, Koller A and Binder BR: Isolation and characterization of plasminogen activators from hyperplastic and malignant prostate tissue. Biochem Biophys Acta 797: 256-265, 1984.
15. Lioita LA, Steeg PS and Stetler-Stevenson WG: Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation. Cell 64: 327-336, 1991.
16. Stahl A and Mueller BM: Binding of urokinase to its receptor promotes migration and invasion of human melanoma cells in vitro. Cancer Res 54 3066-3071, 1994.
17. Blasi F: An upstream enhancer anda and a negative element in the 5' flanking region of the human urokinase plasminogen activator gene. Nucleic Acids Res 16: 10699-10716, 1988.
18. Hammond LA, Brown G, Keedwell RG, Durham J and Chandraratna RA: The prospects of retinoids in the treatment of prostate cancer. Anticancer Drugs 13: 781-90, 2002.
19. Liu T, Pemberton PA and Robertson AD: Three-state unfolding and self-association of maspin, a tumor-suppressing serpin. J Biol Chem 274: 29628-29632, 1999.
20. Swiercz R, Keck RW, Skrzypaczak-Jankun E, Selman SH and Jankun J: Recombinant PAI-1 inhibits angiogenesis and reduces size of LNCaP prostate cancer xenografts in SCID mice. Oncol Rep 8: 463-470, 2001.
21. Kim SJ, Shiba E, Tsukamoto F, Izukura M, Taguchi T, Yoneda K, Tanji Y, Kimoto Y and Takai SI: The expression of urokinase type plasminogen activator is a novel prognostic factor in Dukes' B and C colorectal cancer. Oncol Rep 5: 431-435, 1998.
22. Stephenson J: Study indicates utility for new breast cancer prognosis marker. JAMA 285: 3077-3078, 2001.
23. Gavlis FD, Keer HN, Wilson MJ, Kwaan HC, Sinha AA and Kozlowski JM: Plasminogen activators in human prostate cancer cell lines and tumors: correlation with the aggressive phenotype. J Urol 142: 193-198, 1989.
24. Keer HN, Gavlis FD, Kozlowski JM, Kwaan HC, Bauer KD, Sinha AA and Wilson MJ: Heterogeneity in plasminogen activator (PA) levels in human prostate cancer cell lines: increased PA activity correlates with biologically aggressive behavior. Prostate 18: 201-214, 1991.